Group 1 - "*ST Suwu" (600200) has received a decision from the Shanghai Stock Exchange to terminate its stock listing, effective December 1, 2025, with a trading period for delisting starting on December 9, 2025, lasting for 15 trading days [1] - The Shanghai Stock Exchange will implement strict measures against abnormal trading behaviors related to the aforementioned stocks, which may include monitoring accounts, suspending trading, and restricting account activities [2] - "HeFu China" (603122) has experienced significant stock price fluctuations, with its stock price deviating sharply from its fundamentals, indicating potential risks of market overreaction and irrational speculation [1][2] Group 2 - "Haiwang Biological" (000078) has shown signs of impulsive trading behavior, prompting the Shenzhen Stock Exchange to take notice [2]

以上信息均来自公开资料。本公司对这些信息的准确性和完整性不作任何保证，也不保证所包含的信息和建议不会发生任何变更。我们仅对公开资料中的 内容做原文提取与版式整理，不代表本公司观点，不构成投资建议，并非作为买卖、认购证券或其它金融工具的邀请或保证，投资者据此做出的任何投资 决策与本公司无关。投资有风险，入市需谨慎。本文内容禁止第三方机构单独摘引、截取或以其他不恰当方式转播。 尊敬的投资者： 尊敬的投资者： 近期，深圳证券交易所对"海王生物（000078）"股票进行重点监控，对频繁大量参与该股交易、存在异常交易行为的投资者从严监管。敬请广大投资者合 法合规、理性审慎参与该股交易。 兴业证券股份有限公司 2025年12月8日 兴业证券股份有限公司 2025年12月8日 以上信息均来自公开资料。本公司对这些信息的准确性和完整性不作任何保证，也不保证所包含的信息和建议不会发生任何变更。我们仅对公开资料中的 内容做原文提取与版式整理，不代表本公司观点，不构成投资建议，并非作为买卖、认购证券或其它金融工具的邀请或保证，投资者据此做出的任何投资 决策与本公司无关。投资有风险，入市需谨慎。本文内容禁止第三方机构单独摘引、截取或 ...

海王生物今日下跌2.84%，全天换手率29.10%，成交额40.37亿元，振幅16.33%。龙虎榜数据显示，营业 部席位合计净卖出7759.48万元。 海王生物12月8日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 国信证券股份有限公司浙江互联网分公司 | 10473.98 | 2928.14 | | 买二 | 东方财富证券股份有限公司昌都两江大道证券营业部 | 7130.56 | 2649.58 | | 买三 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 5029.61 | 2554.88 | | 买四 | 东方财富证券股份有限公司拉萨金融城南环路证券营业 部 | 4718.82 | 2797.50 | | 买五 | 东方财富证券股份有限公司山南香曲东路证券营业部 | 4691.65 | 2051.46 | | 卖一 | 华泰证券股份有限公司深圳前海证券营业部 | 8.48 | 6420.21 | | 卖二 | 开源证券股份有限公司西安西大街证券营业部 | ...

New Stock Issuance - New stocks issued include 纳百川 (code: 301667) at an issuance price of 22.63 and 优迅股份 (code: 787807) at 51.66[1] Rights Issues and Announcements - 荃银高科 (code: 300087) has a tender offer period from December 4, 2025, to January 5, 2026[1] - 天普股份 (code: 605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] Delisting and Special Notices - *ST广道 (code: 920680) will enter the delisting arrangement period starting December 11, 2025[1] - *ST苏吴 (code: 600200) will enter the delisting arrangement period starting December 9, 2025[1] Stock Performance Alerts - 赛微电子 (code: 300456) reported severe abnormal fluctuations[1] - 海王生物 (code: 000078) and 瑞达期货 (code: 002961) also reported significant fluctuations[1] Additional Stock Announcements - 航天发展 (code: 000547) and 顺灏股份 (code: 002565) have issued announcements regarding their stock performance[1]

据天眼查APP显示，深圳市海王生物工程股份有限公司成立于1992年12月13日，注册资本263112.3257 万人民币。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 数据宝统计，截至14:38，海王生物成交额37.37亿元，创上市以来新高。最新股价下跌2.46%，换手率 26.88%。上一交易日该股全天成交额为31.00亿元。 （原标题：海王生物成交额创上市以来新高） ...

Group 1: National Medical Insurance and Commercial Health Insurance - The National Healthcare Security Administration has released the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs, of which 50 are first-class innovative drugs, achieving a success rate of 88%, an increase from 76% in 2024 [1] - The updated National Medical Insurance Drug Catalog will be implemented starting January 1, 2026, marking the eighth adjustment since the establishment of the National Healthcare Security Administration and the first introduction of a commercial health insurance innovative drug catalog [1] Group 2: Haiwang Bio - Haiwang Bio announced that its stock price had deviated significantly, with a cumulative increase of over 100% from November 26 to December 5, 2025, indicating severe abnormal trading [2] - The company reported a price-to-book ratio of 7.64, which differs from industry peers, suggesting potential risks of market overheating and irrational speculation [2] Group 3: Shengxiang Bio - Shengxiang Bio disclosed that 20.72 million shares (3.58% of total shares) owned by shareholder Chen Wenyin are subject to judicial freezing, with a provision allowing for the sale of up to 4 million shares under specific conditions [3] - The judicial freeze may exert short-term pressure on the stock price, but the set minimum price for the sale provides some stability [3] Group 4: Kang En Bei Management Changes - Kang En Bei announced the resignation of Chairman Jiang Yi and board member Jiang Qian due to work adjustments, raising concerns about potential governance structure changes [4] - The departure of key executives may lead to market apprehension, but if there are no significant changes in business strategy, growth potential remains [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）股票价格于2025年12月3日至2025 年12月5日连续三个交易日内日收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》 的相关规定，属于股票交易异常波动的情形。同时，截至2025年12月5日收盘，公司股票于2025年11月 26日至2025年12月5日连续8个交易日内日收盘价格涨幅偏离值累计超过100%，根据《深圳证券交易所 交易规则》的相关规定，属于股票交易严重异常波动的情形。 2、经公司自查，并向公司控股股东及实际控制人发函核实，截至目前，不存在对公司应披露而未披露 的重大信息。 3、截至2025年12月5日，公司市净率为7.64倍，与同行业情况存在差异，存在市场情绪过热、非理性炒 作风险，未来可能存在股价快速下跌的风险，敬请广大投资者注意二级市场交易风险，理性决策，审慎 投资。 4、2024年度公司实现营业收入303.17亿元，归属于上市公司股东的净利润-11.9 ...

Core Viewpoint - The stock price of Shenzhen Haiwang Biological Engineering Co., Ltd. has experienced significant fluctuations, with a cumulative increase of over 100% in the closing price over eight consecutive trading days, indicating severe abnormal trading conditions [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price increased by more than 20% over three consecutive trading days from December 3 to December 5, 2025, qualifying as an abnormal trading fluctuation [2][4]. - The stock's price deviation reached a cumulative increase of 105.64% over eight trading days from November 26 to December 5, 2025, indicating severe abnormal trading conditions [11]. Group 2: Company Financial Performance - In 2024, the company achieved a revenue of 30.317 billion yuan, with a net loss attributable to shareholders of 1.193 billion yuan [3]. - For the first three quarters of 2025, the company reported a revenue of 21.513 billion yuan and a net profit of 25.703 million yuan [3]. Group 3: Company Operations and Information Disclosure - The company has confirmed that there are no undisclosed significant matters that should have been disclosed according to the Shenzhen Stock Exchange regulations [10]. - The company has not identified any major changes in its production and operational conditions, and the internal and external business environment remains stable [7].

证券日报网讯12月5日晚间，海王生物（000078）发布风险提示公告称，公司股票于2025年11月26日至 2025年12月5日连续8个交易日内日收盘价格涨幅偏离值累计超过100%，属于股票交易严重异常波动的 情形；经公司自查并向控股股东及实际控制人发函核实，截至目前，不存在对公司应披露而未披露的重 大信息。 ...

Market Performance - The A-share market indices collectively rose during the week of December 1 to December 5, with the Shanghai Composite Index closing at 3902.81 points, up 0.70% for the week [1] - The Shenzhen Component Index closed at 13147.68 points, up 1.08%, and the ChiNext Index closed at 3109.30 points, up 1.36% [1] - A total of 1818 stocks rose while 464 stocks fell during the week, with 87 stocks rising over 15% and 17 stocks falling over 15% [1] Sector Performance - The aerospace equipment, industrial metals, and engineering machinery sectors led the gains, with increases of 10.42%, 9.14%, and 5.86% respectively on December 5 [1] - Conversely, the advertising marketing, digital media, and decoration sectors saw declines of -6.99%, -6.70%, and -3.55% respectively [1] Top Performing Stocks - The top-performing stock, Jiarong Technology (301148.SZ), achieved a weekly increase of 67.18%, followed by Zhaobiao Co. (301136.SZ) with a 58.43% rise [1][2] - Other notable gainers included Haiwang Biological (000078.SZ) and Aerospace Development (000547.SZ), both with weekly increases exceeding 52% [1] Local Stock Activity - Jiarong Technology, a local environmental protection company, specializes in membrane separation technology and has seen significant stock performance [2] - The local stocks in Fujian experienced a surge, with multiple companies hitting their daily price limits, including Hai Xin Food and An Ji Food [2] Policy Support - Fujian province has implemented new policies to support cross-strait integration and development, including measures to enhance the operational environment for Taiwanese enterprises [3][4] - Specific measures include increasing land and sea guarantees for Taiwanese businesses and optimizing tax services for Taiwanese enterprises [3] Financial Performance - The Fujian sector reported a total net profit of 206.36 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 22.73% compared to 168.14 billion yuan in the same period last year [5] Underperforming Stocks - The worst-performing stock, *ST Lifang (300344.SZ), saw a weekly decline of 48.21%, attributed to financial misconduct and impending delisting risks [5][6] - The company has faced significant penalties for inflating revenue figures and is under investigation for serious violations of securities laws [6][7]